INCREASED network capacity created by medtech firm, MedAdvisor's deal with Australian Pharmaceutical Industries (API) is delivering revenue growth for the company.
In a statement to the Australian Securities Exchange, MedAdvisor reported revenue growth in Australia for the first half of the 2022 financial year was up 33% on the prior corresponding period, following the announcement of a five-year agreement with the wholesaler, which added close to 250 Priceline Pharmacy stores to its network (PD 30 Jul 2021).
The company noted that more than 4,000 pharmacies across the country were signed up to use its platform as of 31 Dec 2021, up from 3,700 on 30 Jun 2021.
MedAdvisor reported that the COVID-19 vaccination rollout has played a significant role in fueling transaction growth with more than 3 million doses administered through pharmacies using its products.
The number of patients using MedAdvisor has grown by approximately 400,000 since 20 Jun 2021, with its new V6 platform delivering a positive customer experience.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jan 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jan 22
